A detailed history of Bank Of America Corp transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 896,996 shares of VTYX stock, worth $2.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
896,996
Previous 413,134 117.12%
Holding current value
$2.02 Million
Previous $954,000 104.93%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.85 - $3.2 $895,144 - $1.55 Million
483,862 Added 117.12%
896,996 $1.96 Million
Q2 2024

Aug 14, 2024

BUY
$2.31 - $5.59 $253,855 - $614,307
109,894 Added 36.24%
413,134 $954,000
Q1 2024

May 15, 2024

BUY
$1.9 - $10.13 $477,576 - $2.55 Million
251,356 Added 484.46%
303,240 $1.67 Million
Q4 2023

Feb 14, 2024

SELL
$2.08 - $31.18 $38,070 - $570,687
-18,303 Reduced 26.08%
51,884 $128,000
Q2 2023

Aug 14, 2023

SELL
$28.53 - $39.55 $213,718 - $296,269
-7,491 Reduced 9.64%
70,187 $2.3 Million
Q1 2023

May 12, 2023

BUY
$29.51 - $46.65 $706,705 - $1.12 Million
23,948 Added 44.57%
77,678 $2.6 Million
Q4 2022

Feb 10, 2023

BUY
$24.16 - $36.38 $1.04 Million - $1.56 Million
42,965 Added 399.12%
53,730 $1.76 Million
Q3 2022

Nov 14, 2022

SELL
$12.64 - $38.7 $65,702 - $201,162
-5,198 Reduced 32.56%
10,765 $375,000
Q2 2022

Aug 12, 2022

SELL
$11.95 - $18.75 $175,868 - $275,943
-14,717 Reduced 47.97%
15,963 $195,000
Q1 2022

May 16, 2022

SELL
$10.0 - $19.98 $162,470 - $324,615
-16,247 Reduced 34.62%
30,680 $416,000
Q4 2021

Feb 08, 2022

BUY
$14.2 - $23.07 $666,363 - $1.08 Million
46,927 New
46,927 $932,000

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $127M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.